Recent studies show that the Bruton’s tyrosine kinase (BTK) degrader developed by Haisco Pharmaceutical exhibits significant anti-proliferative activity against the OCI-LY10 cell line in preclinical experiments, with strong antitumor efficacy confirmed in subcutaneous xenograft models. At the same time, DZD8586, the world’s first LYN/BTK dual-target inhibitor developed by Dizal Pharmaceutical, has received Fast Track designation from the U.S. FDA, bringing new hope for overcoming BTK resistance. As innovative strategies such as BTK-PROTAC degraders and dual-target inhibitors continue to emerge, the OCI-LY10 cell line remains a critical tool in drug screening and mechanistic studies, driving progress in the field of lymphoma therapy.
BTK is a key signaling molecule in the B-cell receptor (BCR) signaling pathway and is essential for B-cell development, differentiation, and survival. Mutations in the BTK gene or aberrant activation of the pathway can lead to malignant proliferation of B cells, resulting in various hematologic malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL). In these malignancies, BTK inhibitors suppress tumor cell growth, migration, and adhesion and induce apoptosis by blocking BTK enzymatic activity and disrupting BCR signaling. Meanwhile, in autoimmune diseases, abnormal B-cell activation produces pathogenic autoantibodies and triggers inflammatory responses. Currently, BTK has become one of the core targets for targeted therapy.
Image Biological Functions of BTK
- After BCR activation, BTK is recruited to the plasma membrane and phosphorylated by Lyn/Syk, subsequently activating PLCγ2, increasing intracellular Ca2+ levels, and triggering activation of the NF-κB and MAPK pathways.
- BTK is involved in inflammation and autoimmune responses. In multiple sclerosis and other autoimmune diseases, BTK is also expressed in B cells and microglia, where it exacerbates inflammatory responses by regulating intracellular signaling; BTK inhibitors (BTKi) can reduce myeloid cell infiltration and suppress the release of inflammatory cytokines.
The survival of OCI-LY10 cells is highly dependent on the BCR signaling pathway and its downstream NF-κB pathway. This makes it a classic model for studying drugs targeting these pathways, such as BTK inhibitors. On one hand, the OCI-LY10 cell line shows good responsiveness in BTK inhibitor screening and can model B-cell activation processes observed in diseases such as CLL. On the other hand, OCI-LY10 is relatively insensitive or shows low sensitivity to the first-generation BTK inhibitor ibrutinib (Ibrutinib), compared with other ABC cell lines such as TMD8. This characteristic makes it an ideal model for studying primary resistance mechanisms and developing combination therapy strategies.
The use of BTK inhibitors in the OCI-LY10 cell line demonstrates strong therapeutic potential. Studies indicate that treatment with BTK inhibitors significantly suppresses proliferation of OCI-LY10 cells, improves regulation of the cell cycle, and reduces tumor cell viability.
In the future, as more novel BTK-targeted agents, such as non-covalent inhibitors and dual-target inhibitors, enter the research stage, OCI-LY10 will continue to play a key role as an important DLBCL model cell line.
In vivo validation of OCI-LY10–related models:
References:
- Wen T, Wang J, Shi Y, et al. Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances[J]. Leukemia. 2021, 35(2):312-332.
- Montoya S, et al. Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127[J]. Science. 2024, 383(6682).
- Blombery P, et al. Acquisition of the recurrent BTK L528W mutation during ibrutinib therapy for CLL confers increased on-target resistance[J]. Blood Adv. 2022, 6(8):2252-2256.
